Clear Harbor Asset Management LLC Purchases 4,300 Shares of Johnson & Johnson (NYSE:JNJ)

Clear Harbor Asset Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 11.5% in the 3rd quarter, Holdings Channel reports. The firm owned 41,703 shares of the company’s stock after buying an additional 4,300 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Clear Harbor Asset Management LLC’s investment portfolio, making the stock its 21st biggest position. Clear Harbor Asset Management LLC’s holdings in Johnson & Johnson were worth $5,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of other hedge funds have also recently modified their holdings of the stock. Zions Bancorporation N.A. increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after buying an additional 73 shares in the last quarter. Portland Global Advisors LLC increased its position in Johnson & Johnson by 0.9% in the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after purchasing an additional 78 shares during the period. Vishria Bird Financial Group LLC increased its position in Johnson & Johnson by 3.0% in the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after purchasing an additional 80 shares during the period. Alta Capital Management LLC increased its position in Johnson & Johnson by 3.9% in the third quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after purchasing an additional 82 shares during the period. Finally, G&S Capital LLC increased its position in Johnson & Johnson by 1.8% in the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after purchasing an additional 84 shares during the period. 72.25% of the stock is owned by hedge funds and other institutional investors.

Shares of JNJ stock opened at $133.00 on Friday. The stock has a 50-day moving average price of $130.83 and a 200 day moving average price of $134.05. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The firm has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The firm had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter last year, the business earned $2.05 earnings per share. The company’s revenue was up 1.9% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

A number of analysts recently commented on the company. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Friday, October 11th. Wells Fargo & Co lowered their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Finally, Raymond James lowered their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What does a dividend yield signify to investors?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Leave a Reply

Your email address will not be published. Required fields are marked *

*